Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

ConditionLiver Cancer, Adult

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:

* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

Eligibility criteria

Qualifiers

age ≥ 18 years

diagnosis of HCC

execution of laboratory tests and subsequent treatments and follow-up at our center.

obtained written informed consent to the study participation

Disqualifiers

immune-related concomitant diseases

HIV infection

Trial design

Treatments tested in this trial

Immunochemotherapy combined with antiangiogenic

Treatment groups

100 Participants

are divided into 1 treatment group

Sponsors and collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

Source ClinicalTrials.gov